During 2018 Q4 the big money sentiment decreased to 1.21. That’s change of 0.20, from 2018Q3’s 1.41. 13 investors sold all, 64 reduced holdings as Pacira Pharmaceuticals, Inc. ratio dived. 56 grew positions while 37 funds acquired positions. Funds hold 39.33 million shares thus 0.69% less from 2018Q3’s 39.60 million shares.
Millennium Lc has invested 0.08% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). 30,219 are owned by Martingale Asset Mgmt Ltd Partnership. New York-based Opus Point Prns Mngmt Limited Liability Corporation has invested 1.07% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Hillsdale Inv Mgmt invested 0.05% of its capital in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Rock Springs Capital Mngmt Limited Partnership accumulated 1.25 million shs. 15,437 were reported by Jefferies Group Limited Liability Com. Baillie Gifford And holds 0.05% of its capital in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 933,541 shs. Moreover, Panagora Asset Mgmt has 0% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Amer Intl Gp Incorporated invested in 0% or 26,269 shs. Macquarie Group Ltd has 2.14 million shs. Jacobs Levy Equity has invested 0.08% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Pictet Asset Management Ltd reported 127,600 shs or 0.01% of all its holdings. The Illinois-based Citadel Limited Liability Co has invested 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Clearbridge Investments Ltd Liability Company has 0.05% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 1.15M shs. Keybank Association Oh owns 8,387 shs.

Pacira Pharmaceuticals, Inc. had 6 insider sales and 3 insider buys since November 2, 2018. This’s net activity of $7.33 million. PACE GARY W also bought $207,810 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shs. On Friday, November 2 Riker Lauren Bullaro sold $54,350 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 1,000 shs. Kronenfeld Mark A. bought 1,700 shs worth $66,244. Shares for $3.34 million were sold by Wicki Andreas on Thursday, November 15.

Change of 6.75% for Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s shorted shares was noted. FINRA issued shorted shares of PCRX’s total 2.38 million shares. Previously was reported up change of 6.75% from 2.23 million shares. 4 days will cost PCRX with 665,100 average volume to restore its previous position. Pacira Pharmaceuticals Inc’s shorted shares float is 6.89%.

Ticker’s shares touched $36.39 during the last trading session after 0.49% change.Currently Pacira Pharmaceuticals, Inc. is uptrending after 24.65% change in last April 18, 2018. PCRX has also 143,067 shares volume. PCRX outperformed by 20.28% the S&P 500.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States.The company has $1.50 billion market cap. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.Currently it has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage

A total of 8 analysts rate Pacira Pharmaceuticals (NASDAQ:PCRX) as follows: 3 “Buy”, 3 “Hold” and 2 “Sell”. Тherefore 38% are bullish. (NASDAQ:PCRX) has 12 ratings reports on Apr 18, 2019 according to StockzIntelligence. On Friday, March 1 the company was maintained by H.C. Wainwright. On Friday, November 2 the stock has “Market Perform” rating by BMO Capital Markets. On Monday, March 4 the stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Buy” rating by Wedbush. On Thursday, February 28 the firm has “Sell” rating given by Mizuho. On Friday, March 1 the firm has “Hold” rating given by BMO Capital Markets. The stock rating was maintained by Mizuho with “Sell” on Wednesday, March 6. On Friday, November 2 the rating was maintained by JP Morgan with “Neutral”. The stock rating was maintained by Stifel Nicolaus with “Sell” on Friday, March 8. In Friday, November 2 report JMP Securities maintained the stock with “Market Outperform” rating. The stock rating was downgraded by Mizuho to “Underperform” on Friday, February 1.

For more Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) news published briefly go to: Seekingalpha.com, Seekingalpha.com, Globenewswire.com, Benzinga.com or Benzinga.com. The titles are as follows: “Pacira Pharmaceuticals beats by $0.20, beats on revenue – Seeking Alpha” published on February 28, 2019, “Pacira completes MyoScience takeover – Seeking Alpha” on April 09, 2019, “Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results – GlobeNewswire” with a publish date: November 01, 2018, “HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results – Benzinga” and the last “Pacira (NASDAQ:PCRX) Shares Look Expensive, Stifel Says In Bearish Initiation – Benzinga” with publication date: September 14, 2018.